Novartis’s Kisqali wins FDA breakthrough therapy designation for treating breast cancer patients

Novartis’s Kisqali has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.

The designation covers initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor, reports Reuters.

It was based on results released last month from a Phase III MONALEESA-7 trial demonstrating Kisqali in combination with tamoxifen or an aromatase inhibitor significantly prolonged progression-free survival compared to endocrine therapy alone.

Have your say, we value it!

wise people got already engaged

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
Scroll Up